Affiliations 

  • 1 Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Viet Nam
  • 2 Department of Infectious Disease, Imperial College London, London, United Kingdom
  • 3 Hospital for Tropical Diseases, Ho Chi Minh city, Viet Nam
  • 4 Angkor Hospital for Children, Siem Reap, Cambodia
  • 5 University of Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 6 Hospital Nacional de Niños Benjamin Bloom, San Salvador, El Salvador
  • 7 Centre for Tropical Medicine and Global health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
  • 8 Section Clinical Tropical Medicine, Department for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
  • 9 Independent consultant, Issaquah, United States
  • 10 Consultant, Intellectual Ventures, Global Good Fund, Bellevue, United States
  • 11 UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
Elife, 2021 06 22;10.
PMID: 34154705 DOI: 10.7554/eLife.67460

Abstract

Background: Early identification of severe dengue patients is important regarding patient management and resource allocation. We investigated the association of 10 biomarkers (VCAM-1, SDC-1, Ang-2, IL-8, IP-10, IL-1RA, sCD163, sTREM-1, ferritin, CRP) with the development of severe/moderate dengue (S/MD).

Methods: We performed a nested case-control study from a multi-country study. A total of 281 S/MD and 556 uncomplicated dengue cases were included.

Results: On days 1-3 from symptom onset, higher levels of any biomarker increased the risk of developing S/MD. When assessing together, SDC-1 and IL-1RA were stable, while IP-10 changed the association from positive to negative; others showed weaker associations. The best combinations associated with S/MD comprised IL-1RA, Ang-2, IL-8, ferritin, IP-10, and SDC-1 for children, and SDC-1, IL-8, ferritin, sTREM-1, IL-1RA, IP-10, and sCD163 for adults.

Conclusions: Our findings assist the development of biomarker panels for clinical use and could improve triage and risk prediction in dengue patients.

Funding: This study was supported by the EU's Seventh Framework Programme (FP7-281803 IDAMS), the WHO, and the Bill and Melinda Gates Foundation.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.